標(biāo)題: Titlebook: Cardiorenal Syndrome in Heart Failure; W. H. Wilson Tang,Frederik H. Verbrugge,Wilfried M Book 2020 Springer Nature Switzerland AG 2020 Ca [打印本頁] 作者: OAK 時間: 2025-3-21 19:08
書目名稱Cardiorenal Syndrome in Heart Failure影響因子(影響力)
書目名稱Cardiorenal Syndrome in Heart Failure影響因子(影響力)學(xué)科排名
書目名稱Cardiorenal Syndrome in Heart Failure網(wǎng)絡(luò)公開度
書目名稱Cardiorenal Syndrome in Heart Failure網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cardiorenal Syndrome in Heart Failure被引頻次
書目名稱Cardiorenal Syndrome in Heart Failure被引頻次學(xué)科排名
書目名稱Cardiorenal Syndrome in Heart Failure年度引用
書目名稱Cardiorenal Syndrome in Heart Failure年度引用學(xué)科排名
書目名稱Cardiorenal Syndrome in Heart Failure讀者反饋
書目名稱Cardiorenal Syndrome in Heart Failure讀者反饋學(xué)科排名
作者: 主講人 時間: 2025-3-21 23:48 作者: penance 時間: 2025-3-22 02:25 作者: HAIL 時間: 2025-3-22 06:23
P. Bach,S. Cluzeau,C. Lambermontuts into central autonomic nuclei responsible for cardiovascular control and sympathetic outflow. In disease states such as heart failure and renal failure, increased renal sympathetic nerve activity can further worsen renal function, with a shift from inhibitory to “l(fā)ess inhibitory” (or potentially作者: 種植,培養(yǎng) 時間: 2025-3-22 09:04
https://doi.org/10.1007/978-1-349-26729-3ir effectiveness or induce worrisome worsening of renal function. It is important to understand and leverage the pharmacokinetic and pharmacodynamic properties of diuretic drugs, if therapeutic success is to be achieved. At its simplest, a diuretic must be administered or ingested and absorbed, must作者: ABASH 時間: 2025-3-22 13:27 作者: ABASH 時間: 2025-3-22 17:49 作者: crumble 時間: 2025-3-22 23:11
https://doi.org/10.1007/978-1-349-26729-3ent hemodialysis itself causes significant hemodynamic stress and vascular changes as well as a potential high-output state from arteriovenous fistula that can be linked to left ventricular hypertrophy and myocardial ischemia and stunning. Cardiovascular and metabolic changes such as fluid overload,作者: Amenable 時間: 2025-3-23 01:48 作者: 滑稽 時間: 2025-3-23 07:43
https://doi.org/10.1007/978-1-349-26729-3chieve symptomatic relief. The management of heart failure through the use of intravenous diuretics is at times limited due to renal function. An elevated Cr level, which has previously been associated with poor outcomes, is a common end-point in most AHF trials. However, recent data has called into作者: TIGER 時間: 2025-3-23 12:05 作者: 萬靈丹 時間: 2025-3-23 14:48 作者: 種植,培養(yǎng) 時間: 2025-3-23 18:08
https://doi.org/10.1007/BFb0016562 remain relatively understudied and unrecognized in heart failure. Literature from intensive care medicine, recognizes that an increase in IAP (defined as IAP?>?8?mmHg), is an independent predictor for adverse outcome. A limited amount of data indicates that in ADHF, the prevalence of an IAP above 8作者: 商品 時間: 2025-3-24 00:06 作者: 有法律效應(yīng) 時間: 2025-3-24 04:34 作者: 踉蹌 時間: 2025-3-24 09:46
https://doi.org/10.1007/978-4-431-55111-9ailure. Although irreversible renal dysfunction and treatment with renal replacement therapy are considered an absolute contraindication to left ventricular assist device (LVAD) implantation as destination therapy, advanced heart failure patients with recent onset renal dysfunction should not be exc作者: pacific 時間: 2025-3-24 11:01 作者: Negligible 時間: 2025-3-24 16:29 作者: THE 時間: 2025-3-24 19:54 作者: Inscrutable 時間: 2025-3-25 00:52
W. H. Wilson Tang,Frederik H. Verbrugge,Wilfried MFeatures a multidisciplinary approach with contributions from both cardiologists and nephrologists.Contains a practically applicable case-based approach to managing patients with refractory congestion作者: 不感興趣 時間: 2025-3-25 04:47 作者: 詞匯表 時間: 2025-3-25 10:41 作者: demote 時間: 2025-3-25 12:34 作者: FEAS 時間: 2025-3-25 18:55
Mechanisms of Cardiorenal Syndrome: From Molecular Pathways to Novel Therapeuticsel therapeutic for CRS and acute kidney injury (AKI). CRRL269 possesses renal enhancing properties with RAAS suppression and less hypotension than native NPs, thus representing a new and innovative drug for renoprotection in HF. The combination of using NP urinary biomarkers and designer NP therapeu作者: SEMI 時間: 2025-3-25 20:54 作者: apiary 時間: 2025-3-26 02:08 作者: HPA533 時間: 2025-3-26 06:00
A Patient with Abdominal Congestionvenous congestion. Interestingly, strategies that result in a resolution of the increased IAP in ADHF (e.g. paracentesis or ultrafiltration), have been shown to result in an improvement of renal function. This chapter focusses on the role of abdominal congestion in heart failure.作者: 調(diào)整校對 時間: 2025-3-26 10:14 作者: CBC471 時間: 2025-3-26 15:41 作者: LARK 時間: 2025-3-26 18:32
S. Subramanian,J. R. W. Woittiezel therapeutic for CRS and acute kidney injury (AKI). CRRL269 possesses renal enhancing properties with RAAS suppression and less hypotension than native NPs, thus representing a new and innovative drug for renoprotection in HF. The combination of using NP urinary biomarkers and designer NP therapeu作者: MILK 時間: 2025-3-27 00:12
P. Bach,S. Cluzeau,C. Lambermontgate these maladaptive responses in heart failure. The potential for renal nerves to reinnervate may significantly impact the long-term efficacy of this procedure. Definitive testing in long-term outcome studies in humans should inform the role that renal nerve denervation may play in heart failure 作者: IVORY 時間: 2025-3-27 02:43 作者: Bumptious 時間: 2025-3-27 07:11 作者: 比目魚 時間: 2025-3-27 11:24 作者: Rheumatologist 時間: 2025-3-27 16:28
sed approach to managing patients with refractory congestion.This comprehensive manual reviews the management of cardiorenal syndrome in heart failure. Chapters are structured in a practically applicable and easy-to-follow format with realistic case vignettes and key clinical management questions an作者: blight 時間: 2025-3-27 21:30 作者: 中國紀(jì)念碑 時間: 2025-3-27 22:35 作者: 考博 時間: 2025-3-28 03:15
Book 2020sy-to-follow format with realistic case vignettes and key clinical management questions and answers, followed by a brief discussion of underlying pathophysiological mechanisms of a patient with cardiorenal syndrome. Building from this case, key questions are posed that are relevant to the clinical m作者: 因無茶而冷淡 時間: 2025-3-28 09:38
Sheldon Landsberger,Gary Swift,Jon Neuhoffo today’s practice. In this narrative, we sought to report a historical overview of cardiorenal interactions and thus render homage to those physicians dedicating their work to this subject. Those physicians have paved the way to an era in which the concept, consequences and pathophysiology of cardiorenal syndrome is much better understood.作者: bile648 時間: 2025-3-28 12:15 作者: mediocrity 時間: 2025-3-28 18:38
https://doi.org/10.1007/978-1-349-26729-3anagement (e.g. drugs and devices) as well as metabolic treatment (e.g. anemia) may attenuate disease progression, while modifications in modalities of renal replacement therapy or renal transplant may provide a more favorable cardiovascular profile.作者: Limpid 時間: 2025-3-28 21:48
https://doi.org/10.1007/978-1-349-26729-3etic treatment are possible strategies that can be put in place to deal with diuretic resistance in patients with heart failure..In this chapter early detection of congestion and treatment of loop diuretic resistance are discussed.作者: Oration 時間: 2025-3-28 23:52
A Historical Perspective on Evolving Concepts of Cardiorenal Syndrome in Heart Failure,o today’s practice. In this narrative, we sought to report a historical overview of cardiorenal interactions and thus render homage to those physicians dedicating their work to this subject. Those physicians have paved the way to an era in which the concept, consequences and pathophysiology of cardiorenal syndrome is much better understood.作者: 外星人 時間: 2025-3-29 03:49 作者: 慟哭 時間: 2025-3-29 08:24
Heart Failure in a Patient with End-Stage Kidney Disease on Renal Replacement Therapyanagement (e.g. drugs and devices) as well as metabolic treatment (e.g. anemia) may attenuate disease progression, while modifications in modalities of renal replacement therapy or renal transplant may provide a more favorable cardiovascular profile.作者: 救護(hù)車 時間: 2025-3-29 15:23 作者: Harass 時間: 2025-3-29 18:53 作者: 闡明 時間: 2025-3-29 20:29 作者: Explosive 時間: 2025-3-30 03:05
https://doi.org/10.1007/978-1-349-26729-3scending limb must not be overcome by compensatory salt reabsorption along other nephron segments. This chapter reviews the normal handling of loop and other diuretics, both under normal circumstances and in the presence of heart or kidney failure. It also makes recommendations for avoiding or treating causes of resistance to their action.作者: 含糊其辭 時間: 2025-3-30 05:09
Abundance patterns in some old stars,s with heart failure. We provide a review of recent diuretic resistance research performed in specific heart failure cohorts and interpret these results in the context of historical literature. We conclude with a discussion of mechanism-based treatment options to restore diuretic efficacy.作者: Herd-Immunity 時間: 2025-3-30 10:52 作者: Pseudoephedrine 時間: 2025-3-30 12:57
https://doi.org/10.1007/978-4-431-55111-9ccompanied by high mortality rates. Whether the type of mechanical circulatory support (MCS) device (pulsatile vs non-pulsatile) has a different effect on renal function remains unknown. The emerging role of percutaneous, short-term MCS devices for the restoration or the preservation of renal function is promising.作者: headlong 時間: 2025-3-30 19:34
Insights on Diuretic Therapy from Clinical and Pharmacologic Perspectivesscending limb must not be overcome by compensatory salt reabsorption along other nephron segments. This chapter reviews the normal handling of loop and other diuretics, both under normal circumstances and in the presence of heart or kidney failure. It also makes recommendations for avoiding or treating causes of resistance to their action.作者: 反饋 時間: 2025-3-30 20:59 作者: HUMP 時間: 2025-3-31 03:48
Low Output Heart Failure: The Cold and Wet Patientse of the cardiorenal syndrome. Although low cardiac output may be the cause of a minority of cases of the cardiorenal syndrome, its contribution when present must be recognized and corrected, if possible, to prevent further renal deterioration and patient demise.作者: 障礙物 時間: 2025-3-31 06:44
Cardiorenal Syndrome in a Patient with Mechanical Circulatory Supportccompanied by high mortality rates. Whether the type of mechanical circulatory support (MCS) device (pulsatile vs non-pulsatile) has a different effect on renal function remains unknown. The emerging role of percutaneous, short-term MCS devices for the restoration or the preservation of renal function is promising.作者: 脫水 時間: 2025-3-31 09:45
Book 2020e. thoroughly reviews cardiorenal syndrome from the perspective of both the cardiologist and nephrologist. Its case-based approach makes it an ideal resource for both practising and trainee cardiology and nephrology practitioners.?.作者: 喚醒 時間: 2025-3-31 17:04
